Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.730
-0.040 (-2.26%)
At close: Jul 11, 2025, 4:00 PM
1.810
+0.080 (4.61%)
After-hours: Jul 11, 2025, 5:55 PM EDT
Gain Therapeutics Employees
As of December 31, 2024, Gain Therapeutics had 25 total employees, including 23 full-time and 2 part-time employees. The number of employees decreased by 7 or -21.88% compared to the previous year.
Employees
25
Change (1Y)
-7
Growth (1Y)
-21.88%
Revenue / Employee
n/a
Profits / Employee
-$837,082
Market Cap
51.13M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
GANX News
- 13 days ago - Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 Mutation - GlobeNewsWire
- 4 weeks ago - Gain Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting - GlobeNewsWire
- 2 months ago - Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders - GlobeNewsWire
- 2 months ago - Gain Therapeutics to Participate at The Citizens Life Sciences Conference - GlobeNewsWire
- 2 months ago - Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders - GlobeNewsWire
- 3 months ago - Gain Therapeutics Announces Poster Presentation at AD/PD 2025 - GlobeNewsWire